Development of population-scale sequencing analysis
Genomics plc and DNAnexus collaborate to develop solutions for population-scale sequencing analysis
Record early stage funding for Oxford projects
Thirty-five Oxford projects received £4.6m in funding from proof-of-concept and seed funds managed by Oxford University Innovation in the last financial year.
New business support network for local businesses and startups
Oxford businesses who wish to share their expertise and resources now have a network through which to engage with entrepreneurs and new Oxford startup ventures. The network is managed and run by the University’s Isis Startup Incubator.
Spinout OrganOx completes European clinical trial
Organox has completed the European multi-center trial of its Organox metra device, which improves the success of liver transplantation.
Oxford develops tiny mesh tube devices to treat brain aneurysms
An Oxford spin-out is developing advanced tiny metallic mesh tube devices invented by engineers and clinicians at the University to treat patients suffering from brain aneurysms.
Summit hits first milestone in Duchenne muscular dystrophy program
Nasdaq-listed Oxford spinout Summit Therapeutics has hit its first research milestone as part of a multiyear strategic alliance with the University of Oxford. The collaboration is focussed on developing future-generation utrophin modulators for the potential treatment of all patients with the progressive muscle wasting disorder Duchenne Muscular Dystrophy.
Spinout Celleron Therapeutics announces encouraging clinical results with cancer drug
Celleron Therapeutics is developing personalised medicine for cancer patients. The company has announced results from its first human trial in patients at Oxford’s Churchill Hospital with advanced treatment-resistant aggressive cancer.
© Oxford University Innovation